RNAi Technologies and Global Markets

  • ID: 3632952
  • Report
  • Region: Global
  • 176 pages
  • BCC Research
15 % OFF
until Dec 31st 2018
1 of 5
The Global Market for RNA Interference Technologies is Expected to Grow from $262.1 Million in 2015 to $392.6 Million in 2020, Registering a CAGR of 8.4%

FEATURED COMPANIES

  • Advirna
  • Benitec Biopharma Ltd.
  • Cerulean Pharma, Inc.
  • Marina Biotech, Inc.
  • Peptimed Inc.
  • RXI Pharmaceuticals Corp.
  • MORE
This report summarizes the global RNAi technologies market by category and by region. The RNAi market is analyzed based on RNAi research tools and reagents as well as on RNAi diagnostics. The report includes sales forecasts from 2015 to 2020.

This report provides:

- An overview of the global market for RNAi technologies which are used in the areas of drug delivery, therapeutics, and diagnostics
- Analyses of global market trends, with data from 2014, estimates for 2015, and projections of compound annual growth rates (CAGRs) through 2020
- A breakdown of the technologies: RNAi for drug delivery (by nanoparticle delivery, nucleic acid delivery, aptamer delivery); RNAi for drug discovery and therapeutics (by diseases); RNAi for disease diagnostics and biomarker development (by diseases); and RNAi for reagents, research tools, and other applications (by application)
- Examination of significant deals in the RNAi technologies sector during the last decade
- A look at commercial opportunities in the RNAi research tools and reagents, drug development, diagnostic, and agriculture markets
- Profiles of major players in the industry

Study Objectives:

This report was conducted to analyze the market prospects of ribonucleic acid interference (RNAi) technology. The report assesses the progress of new RNAi techniques in the areas of research tools and products, therapeutics, diagnostics and agricultural segments. Furthermore, the report evaluates the product usage, research and development, collaborations, market trends and future applications, prospects, challenges, etc. in the RNAi market.

Global RNAi technology is in its nascent state. However, the market holds significant opportunities due to the promising application of RNAi therapeutics in often-fatal diseases like cancer, heart ailments, autoimmune diseases, neurodegenerative disease and others. The RNAi research tools and reagents market is growing well due to its major applications in RNAi therapeutics, diagnostics and agricultural areas. Secondly, various RNAi therapeutics candidates are showing success in advanced stages of their clinical investigations. Further, the availability of RNAi diagnostics tests offer great promises of successful application of RNAi therapeutics and diagnostics in medical settings.

The market projections are based on the commercialized research products and tools and trends in their applications, product development, applications in diagnostics, and investments for RNAi therapeutics, agricultural products and other areas. The report provides present market analysis as well as a projection for the next five years (until 2020). The report includes market analysis, market leaders, manufacturers and market shares, profiles of leading companies, current situations, new developments, patent analysis, regulatory aspects, drivers and other factors of RNAi market.

Use this report to:

- Analyze the market prospects of ribonucleic acid interference (RNAi) technology
- Evaluate the product usage, research and development, collaborations, market trends and future applications, prospects, challenges, etc. in the RNAi market
- Assess the progress of new RNAi techniques in the areas of research tools and products,therapeutics, diagnostics and agricultural segments
- Gain information on the regulatory aspects, drivers and other factors of RNAi market

Highlights:

- The global market for RNA interference technologies is expected to grow from $262.1 million in 2015 to $392.6 million in 2020, registering a compound annual growth rate (CAGR) of 8.4%.
- The RNAi research tools and reagents market is projected to reach $391.0 million in 2020 from $261.1 million in 2015, increasing at a CAGR of 8.4%.
- The RNAi diagnostics market reached $1.0 million in 2015 and should reach $1.6 million by 2020 growing at a CAGR of 9.9%.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Advirna
  • Benitec Biopharma Ltd.
  • Cerulean Pharma, Inc.
  • Marina Biotech, Inc.
  • Peptimed Inc.
  • RXI Pharmaceuticals Corp.
  • MORE
Chapter- 1: INTRODUCTION
- STUDY OBJECTIVES
- REASONS FOR DOING THIS STUDY
- CONTRIBUTIONS OF THE STUDY AND INTENDED AUDIENCE
- SCOPE OF THE STUDY
- METHODOLOGY
- INFORMATION SOURCES
- ANALYST CREDENTIALS

Chapter- 2: EXECUTIVE SUMMARY
- Table Summary : GLOBAL REVENUE FOR RNA INTERFERENCE TECHNOLOGIES BY TYPE, THROUGH 2020
- Figure Summary : GLOBAL REVENUE FOR RNA INTERFERENCE TECHNOLOGIES BY TYPE, 2013-2020

Chapter- 3: OVERVIEW
- RIBONUCLEIC ACID (RNA)
- RNA INTERFERENCE (RNAI)
- RNA INTERFERENCE DRUG DELIVERY
- RNAI DRUG DISCOVERY AND DEVELOPMENT
- OTHER POTENTIAL APPLICATIONS OF RNA INTERFERENCE

Chapter- 4: NEW DEVELOPMENTS AND REGULATORY ACTIVITY
- NEW DEVELOPMENTS
- REGULATORY ASPECTS
- COLLABORATIVE TRIALS AND FUTURE ACTIVITIES

Chapter- 5: MARKET ANALYSIS
- MARKET BY TECHNOLOGY
- MARKET BY REGION

Chapter- 6: INDUSTRY STRUCTURE
- RNAI RESEARCH TOOLS AND REAGENTS
- RNAI DIAGNOSTICS

Chapter- 7: PATENT ANALYSIS
- PATENTS BY YEAR
- PATENTS BY COUNTRY FOR RNA INTERFERENCE TECHNOLOGIES
- PATENTS BY COMPANY FOR RNA INTERFERENCE TECHNOLOGIES
- PATENTS BY ASSIGNEE FOR RNA INTERFERENCE TECHNOLOGIES

Chapter- 8: CURRENT STATUS
- INNOVATIVE TECHNOLOGIES AND PLATFORMS FOR RNA INTERFERENCE
- FACTORS AFFECTING THE RNA INTERFERENCE MARKET
- CURRENT DRIVERS FOR THE RNA INTERFERENCE TECHNOLOGY MARKET
- MERGER AND ACQUISITION ACTIVITIES
- FUNDING FOR DEVELOPMENT OF RNA INTERFERENCE THERAPEUTICS AND TECHNOLOGIES

Chapter- 9: COMPANY PROFILES
- ADVIRNA
- ALNYLAM PHARMACEUTICALS, INC.
- APEIRON BIOLOGICS AG
- APPLIED BIOLOGICAL MATERIALS, INC.
- ARBUTUS BIOPHARMA CORP. (PREVIOUSLY TEKMIRA PHARMACEUTICALS CORP.)
- ARCTURUS THERAPEUTICS, INC.
- ARROWHEAD RESEARCH CORP.
- ASCLETIS INC.
- BENITEC BIOPHARMA LTD.
- BIOGEN IDEC, INC.
- BIOMICS BIOTECHNOLOGIES CO. LTD.
- BIONEER CORP.
- CELLECTA, INC.
- CERULEAN PHARMA, INC.
- DICERNA PHARMACEUTICALS, INC.
- EXIQON A/S
- F. HOFFMANN-LA ROCHE AG (ROCHE)
- GENERAL ELECTRIC CO.
- INTEGRATED DNA TECHNOLOGIES, INC.
- INVIVOGEN
- ISIS PHARMACEUTICALS, INC.
- MARINA BIOTECH, INC.
- MODERNA THERAPEUTICS
- MONSANTO CO.
- NITTO DENKO CORP.
- PEPTIMED INC.
- QIAGEN N.V.
- QUARK PHARMACEUTICALS, INC.
- REGULUS THERAPEUTICS
- ROSETTA GENOMICS LTD.
- RXI PHARMACEUTICALS CORP.
- SANOFI
- SIGMA-ALDRICH
- SILENCE THERAPEUTICS PLC.
- SILENSEED LTD.
- SOLSTICE BIOLOGICS
- SOMAGENICS, INC.
- SUMITOMO DAINIPPON PHARMA CO. LTD.
- SYNGENTA INTERNATIONAL AG
- THE NATIONAL INSTITUTES OF HEALTH (NIH)
- THE RNAI CONSORTIUM AT BROAD INSTITUTE OF MIT AND HARVARD
- THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
- THERMO FISHER SCIENTIFIC, INC.
- ZELTIA GROUP

Chapter- 10: APPENDIX
- GLOSSARY AND ABBREVIATIONS

List of Tables

Summary Table : GLOBAL REVENUE FOR RNA INTERFERENCE TECHNOLOGIES BY TYPE, THROUGH 2020
Table 1 : EVOLUTION OF RNA
Table 2 : MICRORNA (MIRNA) DATABASES
Table 3 : SHORT/SMALL INTERFERING RNA (SIRNA) DATABASES
Table 4 : PIWI-INTERACTING RNA (PIRNA) DATABASES
Table 5 : STABILIZATION METHODS FOR LIPID BASED SIRNA DELIVERY SYSTEM
Table 6 : NEW DEVELOPMENTS IN THE RESEARCH PIPELINE OF RNAI THERAPEUTICS AND TECHNOLOGIES AS OF SEPTEMBER 2015
Table 7 : GLOBAL REVENUE FOR RNAI TECHNOLOGIES BY TYPE, THROUGH 2020
Table 8 : MARKET SHARE OF RNAI TECHNOLOGIES BY TYPE, 2014
Table 9 : MODIFICATIONS OF SIRNA
Table 10 : RNAI VECTORS
Table 11 : GLOBAL REVENUE FOR RNAI RESEARCH TOOLS AND REAGENTS, THROUGH 2020
Table 12 : MARKET SHARE OF RNAI RESEARCH TOOLS AND REAGENTS, 2014
Table 13 : DISEASE-SPECIFIC TARGET GENES/PROTEINS FOR RNAI THERAPEUTICS
Table 14 : GLOBAL PHARMACEUTICAL MARKET, THROUGH 2020
Table 15 : GLOBAL PHARMACEUTICAL MARKET SHARES BY REGION, 2014
Table 16 : TOP GLOBAL PHARMACEUTICAL COMPANIES BY SALES, 2014
Table 17 : GLOBAL OUTLOOK OF THERAPEUTIC SPENDING BY DISEASE, THROUGH 2018
Table 18 : NUMBER OF PUBLICATIONS ASSOCIATED WITH MIRNA AND DISEASES, OCTOBER 2015
Table 19 : MIRNA IN VARIOUS CANCER TYPES
Table 20 : MIRNA AND TARGET GENE PAIRS IN VARIOUS CANCER TYPES
Table 21 : BIOMARKERS IN VARIOUS CANCER TYPES
Table 22 : GLOBAL REVENUE MARKET FOR RNAI DIAGNOSTICS, THROUGH 2020
Table 23 : GLOBAL REVENUE FOR MIRNA RESEARCH TOOLS, THROUGH 2020
Table 24 : SAFETY ISSUES WITH RNAI CROP IMPROVEMENT
Table 25 : PLANT IMPROVEMENT AREAS THROUGH RNAI TECHNOLOGIES
Table 26 : REGIONS, GENES AND APPLICATION OF RNAI-TARGETING ORGANISMS FOR IMPROVEMENT OF CROPS
Table 27 : GLOBAL REVENUE FOR RNAI RESEARCH TOOLS AND REAGENTS BY REGION, THROUGH 2020
Table 28 : GLOBAL MARKET SHARE OF RNAI RESEARCH TOOLS AND REAGENTS BY REGION, 2014
Table 29 : GLOBAL REVENUE FOR RNAI DIAGNOSTICS BY REGION, THROUGH 2020
Table 30 : GLOBAL MARKET SHARE OF RNAI DIAGNOSTICS BY REGION, 2014
Table 31 : LEADING MANUFACTURERS/SUPPLIERS OF RNAI RESEARCH TOOLS AND REAGENTS, 2014
Table 32 : GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR RNAI RESEARCH TOOLS AND REAGENTS, 2014
Table 33 : LEADING MANUFACTURERS/SUPPLIERS OF RNAI DIAGNOSTICS, 2014
Table 34 : MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR RNAI DIAGNOSTICS, 2014
Table 35 : TOTAL NUMBER OF PATENTS BY YEAR, 2013-AUGUST 2015
Table 36 : NUMBER OF U.S. PATENTS FOR RNAI TECHNOLOGIES BY COUNTRY, 2013-AUGUST 2015
Table 37 : PATENT SHARES FOR RNAI TECHNOLOGIES BY COUNTRY, 2013-AUGUST 2015
Table 38 : NUMBER OF U.S. PATENTS FOR RNAI TECHNOLOGIES BY COMPANY, 2013-AUGUST 2015
Table 39 : NUMBER OF PATENTS FOR RNAI TECHNOLOGIES BY TYPE OF ASSIGNEE, 2013-AUGUST 2015
Table 40 : FUNDING FOR DEVELOPMENT OF RNAI-BASED PRODUCTS AND PLATFORMS, 2013-SEPTEMBER 2015
Table 41 : INVESTMENTS FOR DEVELOPMENT OF RNAI-BASED PRODUCTS AND PLATFORMS, 2013-SEPTEMBER 2015

List of Figures

Summary Figure : GLOBAL REVENUE FOR RNA INTERFERENCE TECHNOLOGIES BY TYPE, 2013-2020
Figure 1 : GLOBAL REVENUE FOR RNAI TECHNOLOGIES BY TYPE, 2013-2020
Figure 2 : MARKET SHARE OF RNAI TECHNOLOGIES BY TYPE, 2014
Figure 3 : GLOBAL REVENUE FOR RNAI RESEARCH TOOLS AND REAGENTS, 2013-2020
Figure 4 : MARKET SHARE OF RNAI RESEARCH TOOLS AND REAGENTS, 2014
Figure 5 : GLOBAL PHARMACEUTICAL SALES MARKET,2013-2020
Figure 6 : GLOBAL PHARMACEUTICAL MARKET SHARES BY REGION, 2014
Figure 7 : GLOBAL REVENUE MARKET FOR RNAI DIAGNOSTICS, 2013-2020
Figure 8 : GLOBAL REVENUE FOR MIRNA RESEARCH TOOLS,2013-2020
Figure 9 : GLOBAL REVENUE FOR RNAI RESEARCH TOOLS AND REAGENTS BY REGION, 2013-2020
Figure 10 : GLOBAL MARKET SHARE OF RNAI RESEARCH TOOLS AND REAGENTS BY REGION, 2014
Figure 11 : GLOBAL REVENUE FOR RNAI DIAGNOSTICS BY REGION, 2013-2020
Figure 12 : GLOBAL MARKET SHARE OF RNAI DIAGNOSTICS BY REGION, 2014
Figure 13 : GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR RNAI RESEARCH TOOLS AND REAGENTS, 2014
Figure 14 : MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR RNAI DIAGNOSTICS, 2014
Figure 15 : TOTAL NUMBER OF PATENTS BY YEAR, 2013-AUGUST 2015
Figure 16 : PATENT SHARES FOR RNAI TECHNOLOGIES BY COUNTRY, 2013-AUGUST 2015
Figure 17 : NUMBER OF PATENTS FOR RNAI TECHNOLOGIES BY TYPE OF ASSIGNEE, 2013-AUGUST, 2015
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
- Advirna
- Alnylam Pharmaceuticals, Inc.
- Apeiron Biologics AG
- Applied Biological Materials, Inc.
- Arbutus Biopharma Corp. (Previously Tekmira Pharmaceuticals Corp.)
- Arcturus Therapeutics, Inc.
- Arrowhead Research Corp.
- Ascletis Inc.
- Benitec Biopharma Ltd.
- Biogen Idec, Inc.
- Biomics Biotechnologies Co. Ltd.
- Bioneer Corp.
- Cellecta, Inc.
- Cerulean Pharma, Inc.
- Dicerna Pharmaceuticals, Inc.
- Exiqon A/S
- F. Hoffmann-La Roche Ag (Roche)
- General Electric Co.
- Integrated Dna Technologies, Inc.
- Invivogen
- ISIS Pharmaceuticals, Inc.
- Marina Biotech, Inc.
- Moderna Therapeutics
- Monsanto Co.
- Nitto Denko Corp.
- Peptimed Inc.
- Qiagen N.V.
- Quark Pharmaceuticals, Inc.
- Regulus Therapeutics
- Rosetta Genomics Ltd.
- RXI Pharmaceuticals Corp.
- Sanofi
- Sigma-Aldrich
- Silence Therapeutics Plc.
- Silenseed Ltd.
- Solstice Biologics
- Somagenics, Inc.
- Sumitomo Dainippon Pharma Co. Ltd.
- Syngenta International AG
- The National Institutes of Health (NIH)
- The RNAI Consortium at Broad Institute Of MIT and Harvard
- The University of Texas MD Anderson Cancer Center
- Thermo Fisher Scientific, Inc.
- Zeltia Group
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll